Cited by 333Treatment of Major DepressionElectroconvulsive Therapy StudiesTryptophan and brain disorders

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class

Kim, Jean, Farchione, Tiffany, Potter, Andrew, Chen, Qi, Temple, Robert·2019·New England Journal of Medicine

DOI 10.1056/nejmp1903305

Open this paper in CoChat — free account

Abstract

Interview with Dr. Roy Perlis on esketamine as an option for treatment-resistant depression. (08:16)Download The FDA has approved esketamine, the first antidepressant in a new class, for treatment-resistant depression. The agency weighed the drug’s rapid onset of effect against its abuse potential, which led to a Risk Evaluation and Mitigation Strategy.

Integrity signals

Registry

Crossref · 10.1056/nejmp1903305

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Mortality in Mental Disorders and Global Disease Burden Implications: A Systematic Review and Meta-analysis
Walker, E. R., McGee, R. E., & Druss, B. G. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2502 · Cited by 2,976
Synaptic Mechanisms Underlying Rapid Antidepressant Action of Ketamine
Kavalali, E. T., & Monteggia, L. M. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12040531 · Cited by 258
Treatment-resistant depression and suicidality
Bergfeld, I. O., Mantione, M., Figee, M., Schuurman, P. R., Lok, A., & Denys, D. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.04.016 · Cited by 256
Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications
Khin, N. A., Chen, Y., Yang, Y., Yang, P., & LAUGHREN, T. P. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06191 · Cited by 211

Show all 5 references

Sorted by citations

Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1/Nrf2/HO-1/Gpx4 pathway
Dang, R., Wang, M., Li, X., Wang, H., Liu, L., Wu, Q., Zhao, J., Ji, P., Zhong, L., Licinio, J., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02400-6 · Cited by 547
Depression
McCarron, R. M., Shapiro, B. B., Rawles, J., & Luo, J. S. (2021) · Annals of Internal Medicine · doi:10.7326/aitc202105180 · Cited by 511
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3
Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.008 · Cited by 481
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)
Ionescu, D. F., Fu, D.-J., Qiu, X., Lane, R., Lim, P., Kasper, S., Hough, D., Drevets, W. C., Manji, H., & Canuso, C. M. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa068 · Cited by 418
“Rapid, robust, clinically meaningful reduction in depressive symptoms has been demonstrated in phase 2/3 studies of treatment-resistant depression (Kim et al., 2019) and in a phase 2, proof-of-concept study of depressed patients at imminent risk for suicide (Canuso et al.”
Background
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis
Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Wei, Y., Chang, L., & Hashimoto, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01121-1 · Cited by 248
Depression and Heart Failure: The Lonely Comorbidity
Sbolli, M., Fiuzat, M., Cani, D., & O’Connor, C. M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1865 · Cited by 255
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
The role of dissociation in ketamine’s antidepressant effects
Ballard, E. D., & Zarate, C. A. (2020) · Nature Communications · doi:10.1038/s41467-020-20190-4 · Cited by 231
Neocortical circuits in pain and pain relief
Tan, L. L., & Kuner, R. (2021) · Nature reviews. Neuroscience · doi:10.1038/s41583-021-00468-2 · Cited by 157
New and emerging approaches to treat psychiatric disorders
Scangos, K. W., State, M. W., Miller, A. H., Baker, J. T., & Williams, L. M. (2023) · Nature Medicine · doi:10.1038/s41591-022-02197-0 · Cited by 164
Glutamate-Mediated Excitotoxicity in the Pathogenesis and Treatment of Neurodevelopmental and Adult Mental Disorders
Nicosia, N., Giovenzana, M., Misztak, P., Mingardi, J., & Musazzi, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126521 · Cited by 135
Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
Gastaldon, C., Raschi, E., Kane, J. M., Barbui, C., & Schoretsanitis, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000510703 · Cited by 134
Long-term safety of ketamine and esketamine in treatment of depression
Nikayin, S., Murphy, E., Krystal, J. H., & Wilkinson, S. T. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2066651 · Cited by 128
The molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence
McIntyre, R. S., Rodrigues, N. B., Lee, Y., Lipsitz, O., Subramaniapillai, M., Gill, H., Nasri, F., Majeed, A., Lui, L. M. W., Senyk, O., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.05.088 · Cited by 110
Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial
Wilkinson, S. T., Rhee, T. G., Joormann, J., Webler, R., Ortiz Lopez, M., Kitay, B., Fasula, M., Elder, C., Fenton, L., & Sanacora, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517074 · Cited by 108
Adjunctive intranasal esketamine for major depressive disorder: A systematic review of randomized double-blind controlled-placebo studies
Zheng, W., Cai, D.-B., Xiang, Y.-Q., Zheng, W., Jiang, W., Sim, K., Ungvari, G. S., Huang, X., Huang, X.-X., Ning, Y., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.002 · Cited by 101
Ketamine Rapidly Enhances Glutamate-Evoked Dendritic Spinogenesis in Medial Prefrontal Cortex Through Dopaminergic Mechanisms
Wu, M., Minkowicz, S., Dumrongprechachan, V., Hamilton, P., & Kozorovitskiy, Y. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.12.022 · Cited by 95
Arketamine, a new rapid-acting antidepressant: A historical review and future directions
Zhang, J.-C., Yao, W., & Hashimoto, K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109219 · Cited by 93
GLP-1-directed NMDA receptor antagonism for obesity treatment
Petersen, J., Ludwig, M. Q., Juozaityte, V., Ranea‐Robles, P., Svendsen, C., Hwang, E., Kristensen, A. W., Fadahunsi, N., Lund, J. T., Breum, A. W., et al. (2024) · Nature · doi:10.1038/s41586-024-07419-8 · Cited by 86
Generating comparative evidence on new drugs and devices after approval
Cipriani, A., Ioannidis, J. P. A., Rothwell, P. M., Glasziou, P., Li, T., Hernandez, A. F., Tomlinson, A., Simes, R. J., & Naci, H. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33177-0 · Cited by 89
Ketamine: Neuroprotective or Neurotoxic?
Choudhury, D., Autry, A. E., Tolias, K. F., & Krishnan, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.672526 · Cited by 89
Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data
Efthimiou, O., Taipale, H. T., Raduà, J., Schneider‐Thoma, J., Pinzón-Espinosa, J., Ortuño, M., Vinkers, C. H., Mittendorfer‐Rutz, E., Cardoner, N., Tanskanen, A., et al. (2024) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00366-8 · Cited by 93
International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators
Price, R. B., Kissel, N., Baumeister, A., Rohac, R., Woody, M. L., Ballard, E. D., Zarate, C. A., Deakin, W., Abdallah, C. G., Feder, A., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01757-7 · Cited by 82
Ketamine decreases neuronally released glutamate via retrograde stimulation of presynaptic adenosine A1 receptors
Lazarevic, V., Yang, Y., Flais, I., & Svenningsson, P. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01246-3 · Cited by 81
Generating comparative evidence on new drugs and devices before approval
Naci, H., Salcher‐Konrad, M., Kesselheim, A. S., Wieseler, B., Rochaix, L., Redberg, R. F., Salanti, G., Jackson, E., Garner, S. E., Stroup, T. S., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33178-2 · Cited by 79
Esketamine alleviates postoperative depression-like behavior through anti-inflammatory actions in mouse prefrontal cortex
Wang, T., Weng, H., Zhou, H., Yang, Z., Tian, Z., Xi, B., & Li, Y. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.03.072 · Cited by 81
Serotonin 2A Receptor (5-HT 2A R) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants
Duan, W., Cao, D., Wang, S., & Cheng, J. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00375 · Cited by 81
Effects of Esketamine on Postoperative Negative Emotions and Early Cognitive Disorders in Patients Undergoing Non-Cardiac Thoracic Surgery: A Randomized Controlled Trial
Luo, T., Deng, Z., Ren, Q., Mu, F., Zhang, Y., & Wang, H. (2024) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2024.111447 · Cited by 75
Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis
Medeiros, G. C., Gould, T. D., Prueitt, W. L., Nanavati, J., Grunebaum, M. F., Farber, N. B., Singh, B., Selvaraj, S., Machado-Vieira, R., Achtyes, E. D., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01652-1 · Cited by 75
The impact of perioperative ketamine or esketamine on the subjective quality of recovery after surgery: a meta-analysis of randomised controlled trials
Hung, K., Kao, C., Ho, C., Hsing, C., Chang, Y.-J., Wang, L., Liao, S.-W., & Chen, I. (2024) · British Journal of Anaesthesia · doi:10.1016/j.bja.2024.03.012 · Cited by 82
Antidepressants for the treatment of depression in people with cancer
Vita, G., Compri, B., Matcham, F., Barbui, C., & Ostuzzi, G. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011006.pub4 · Cited by 73
Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency
Nikkheslat, N. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100383 · Cited by 72
Characterizing brain dynamics during ketamine-induced dissociation and subsequent interactions with propofol using human intracranial neurophysiology
Tian, F., Lewis, L. D., Zhou, D. W., Balanza, G. A., Paulk, A. C., Zelmann, R., Peled, N., Soper, D. J., Mercado, L. A. S. C., Peterfreund, R. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37463-3 · Cited by 66
Ketamine for Bipolar Depression: A Systematic Review
Bahji, A., Zarate, C. A., & Vázquez, G. H. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab023 · Cited by 70
Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial
Glue, P., Loo, C. K. A., Fam, J., Lane, H., Young, A. H., Surman, P., BEDROC study investigators, Glozier, N., Fitzgerald, P. B., Liu, D., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03063-x · Cited by 72
A New Rapid-Acting Antidepressant
Krystal, J. H., Charney, D. S., & Duman, R. S. (2020) · Cell · doi:10.1016/j.cell.2020.02.033 · Cited by 63
GluN2A mediates ketamine-induced rapid antidepressant-like responses
Su, T., Lu, Y., Fu, C., Geng, Y., & Chen, Y. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01436-y · Cited by 64
Bridging Rapid and Sustained Antidepressant Effects of Ketamine
Kim, J.-W., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.02.003 · Cited by 59
Self-citation
High Levels of Genetic Diversity within Nilo-Saharan Populations: Implications for Human Adaptation
Mulindwa, J., Noyes, H. A., Ilboudo, H., Pagani, L., Nyangiri, O. A., Kimuda, M. P., Ahouty, B., Asina, O. F., Ofon, E. A., Kamoto, K., et al. (2020) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2020.07.007 · Cited by 60
Molecular mechanisms of psychiatric diseases
Blokhin, I. O., Khorkova, O., Saveanu, R. V., & Wahlestedt, C. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105136 · Cited by 64
Glutamatergic System in Depression and Its Role in Neuromodulatory Techniques Optimization
Khoodoruth, M. A. S., Estudillo‐Guerra, M. A., Pacheco‐Barrios, K., Nyundo, A., Chapa-Koloffon, G., & Ouanes, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.886918 · Cited by 66
Effects of different doses of esketamine intervention on postpartum depressive symptoms in cesarean section women: A randomized, double-blind, controlled clinical study
Yang, S. Q., Zhou, Y., Yang, S. T., Mao, X., Chen, L., Bai, Z.-H., Ping, A. Q., Xu, S. Y., Li, Q. W., Gao, K., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.07.007 · Cited by 58
Off-label uses of drugs for depression
Skånland, S. S., & Cieślar‐Pobuda, A. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172732 · Cited by 59
Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders
Whittaker, E., Dadabayev, A. R., Joshi, S. A., & Glue, P. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211056743 · Cited by 56
Acupuncture Can Play an Antidepressant Role by Regulating the Intestinal Microbes and Neurotransmitters in a Rat Model of Depression
Li, P., Huang, W., Yan, Y., Cheng, W., Liu, S., Huang, Y., Chen, W., Chen, Y., Gao, Y., Lu, W., et al. (2021) · Medical Science Monitor · doi:10.12659/msm.929027 · Cited by 58
Esketamine for treatment resistant depression: a trick of smoke and mirrors?
Gastaldon, C., Papola, D., Ostuzzi, G., & Barbui, C. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796019000751 · Cited by 54
“Three were short-term placebo-controlled efficacy trials conducted in participants suffering from TRD.”
BackgroundMethodInfluential
Alcohol Exposure Induces Depressive and Anxiety-like Behaviors via Activating Ferroptosis in Mice
Xu, C., Xiong, Q., Tian, X., Liu, W., Sun, B., Ru, Q., & Shu, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213828 · Cited by 56
Mu Opioid Receptor Activation Mediates (S)-ketamine Reinforcement in Rats: Implications for Abuse Liability
Levinstein, M. R., Carlton, M. L., Ianni, T. D., Ventriglia, E. N., Rizzo, A., Gomez, J. L., Budinich, R. C., Shaham, Y., Airan, R. D., Zarate, C. A., et al. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.12.019 · Cited by 51
Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis
Wang, S., Kim, N.-Y., Na, H.-R., Lim, H. K., Woo, Y. S., Pae, C., & Bahk, W. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.2.341 · Cited by 61
Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States
Ross, E. L., & Soeteman, D. I. (2020) · Psychiatric Services · doi:10.1176/appi.ps.201900625 · Cited by 51
Application of Ketamine in Pain Management and the Underlying Mechanism
Ma, X., Yan, J., & Jiang, H. (2023) · Pain Research and Management · doi:10.1155/2023/1928969 · Cited by 51
The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence
Ragnhildstveit, A., Roscoe, J., Bass, L. C., Averill, C. L., Abdallah, C. G., & Averill, L. A. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231154125 · Cited by 54
Role of neurotrophic and growth factors in the rapid and sustained antidepressant actions of ketamine
Deyama, S., & Kaneda, K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109335 · Cited by 46
The effect of pyruvate on the development and progression of post-stroke depression: A new therapeutic approach
Frank, D., Kuts, R., Tsenter, P., Gruenbaum, B. F., Grinshpun, Y., Zvenigorodsky, V., Shelef, I., Natanel, D., Brotfain, E., Zlotnik, A. A., et al. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.035 · Cited by 47
Development of the Ketamine Side Effect Tool (KSET)
Short, B. L., Dong, V., Gálvez, V., Vulovic, V., Martin, D. M., Bayes, A. J., Zarate, C. A., Murrough, J. W., McLoughlin, D. M., Riva‐Posse, P., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.120 · Cited by 47
Approval of esketamine for treatment-resistant depression
Singh, J. B., Daly, E. J., Mathews, M., Fedgchin, M., Popova, V., Hough, D., & Drevets, W. C. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30533-4 · Cited by 46
Role of the AMPA receptor in antidepressant effects of ketamine and potential of AMPA receptor potentiators as a novel antidepressant
Suzuki, A., Hara, H., & Kimura, H. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109308 · Cited by 46
A bibliometric analysis of research on heart failure comorbid with depression from 2002 to 2021
Ying, H., Zhang, X., He, T., Feng, Q., Wang, R., Yang, L., & Duan, J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13054 · Cited by 45
Safety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary review
Moore, T. J., Alami, A., Alexander, G. C., & Mattison, D. R. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2707 · Cited by 46
Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review
Ng, J., Rosenblat, J. D., Lui, L. M. W., Teopiz, K. M., Lee, Y. L., Lipsitz, O., Mansur, R. B., Rodrigues, N. B., Nasri, F., Gill, H., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.06.032 · Cited by 47
Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study
Ochs-Ross, R., Wajs, E., Daly, E., Zhang, Y., Lane, R., Lim, P., Drevets, W. C., Steffens, D. C., Sanacora, G., Jamieson, C., et al. (2021) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2021.09.014 · Cited by 44
Ascending‐Dose Study of Controlled‐Release Ketamine Tablets in Healthy Volunteers: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability
Glue, P., Medlicott, N. J., Surman, P., Lam, F., Hung, N. A., & Hung, C. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1573 · Cited by 42
Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study
Brendle, M., Ahuja, S., Valle, M. D., Moore, C., Thielking, P. D., Malone, D. C., & Robison, R. J. (2022) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2022-0149 · Cited by 42
The Rapidly Shifting Ketamine Landscape in the US
Wilkinson, S. T., Palamar, J. J., & Sanacora, G. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.4945 · Cited by 42
Fast-acting antidepressant-like effects of Reelin evaluated in the repeated-corticosterone chronic stress paradigm
Brymer, K. J., Johnston, J. N., Botterill, J. J., Romay-Tallón, R., Mitchell, M. A., Allen, J., Pinna, G., Caruncho, H. J., & Kalynchuk, L. E. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0609-z · Cited by 42
Mathematical modeling of the transmission of SARS-CoV-2—Evaluating the impact of isolation in São Paulo State (Brazil) and lockdown in Spain associated with protective measures on the epidemic of CoViD-19
Yang, H. M., Lombardi, L. P., Castro, F. F. M., & Yang, A. C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252271 · Cited by 43
Ketamine for the Treatment of Chronic Pain: A Comprehensive Review
Israel, J. E., Pierre, S. S., Ellis, E., Hanukaai, J. S., Noor, N., Varrassi, G., Wells, M., & Kaye, A. D. (2021) · Health Psychology Research · doi:10.52965/001c.25535 · Cited by 48
Real‐world effectiveness of repeated ketamine infusions for treatment‐resistant bipolar depression
Fancy, F., Rodrigues, N. B., Di Vincenzo, J. D., Chau, E. H., Sethi, R., Husain, M. I., Gill, H., Tabassum, A., Mckenzie, A., Phan, L., et al. (2023) · Bipolar Disorders · doi:10.1111/bdi.13284 · Cited by 40
Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: A comparative, randomized and double-blind study
Araújo-de-Freitas, L., Santos‐Lima, C., Mendonça-Filho, E., Vieira, F., França, R. J. A. F., Magnavita, G. M., Cardoso, T. L., Correia‐Melo, F. S., Leal, G. C.-G., Jesus‐Nunes, A. P., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114058 · Cited by 41
Inpatient suicide in psychiatric settings: Evaluation of current prevention measures
Chammas, F., Januel, D., & Bouaziz, N. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.997974 · Cited by 38
Neurocognitive Effects of Ketamine and Esketamine for Treatment-Resistant Major Depressive Disorder: A Systematic Review
Souza‐Marques, B., Santos‐Lima, C., Araújo-de-Freitas, L., Vieira, F., Jesus‐Nunes, A. P., Quarantini, L. C., & Sampaio, A. S. (2021) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000312 · Cited by 40
A bibliometric analysis of research on (R)-ketamine from 2002 to 2021
He, T., Wang, D., Wu, Z., Huang, C., Xu, X., Xu, X., Liu, C., Hashimoto, K., & Yang, C. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109207 · Cited by 35
Probabilistic Reinforcement Learning and Anhedonia
Kangas, B. D., Der‐Avakian, A., & Pizzagalli, D. A. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_349 · Cited by 36
Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment
Ng, J., Lui, L. M. W., Rosenblat, J. D., Teopiz, K. M., Lipsitz, O., Cha, D. S., Xiong, J., Nasri, F., Lee, Y. L., Kratiuk, K., et al. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05767-1 · Cited by 34
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Jones, R., Freeman, M. P., Kornstein, S. G., Cooper, K., Daly, E., Canuso, C. M., & Nicholson, S. (2022) · Archives of Women s Mental Health · doi:10.1007/s00737-021-01185-6 · Cited by 33
Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity
Copa, D., Erritzøe, D., Giribaldi, B., Nutt, D. J., Carhart-Harris, R. L., & Tagliazucchi, E. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.02.089 · Cited by 36
Ketamine sensitization: Influence of dose, environment, social isolation and treatment interval
Trujillo, K. A., & Heller, C. Y. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112271 · Cited by 36
Blood glutamate scavenging as a novel glutamate-based therapeutic approach for post-stroke depression
Gruenbaum, B. F., Kutz, R., Zlotnik, A. A., & Boyko, M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320903951 · Cited by 32
Ketamine Treatment for Alcohol Use Disorder: A Systematic Review
Kelson, M., Burnett, J. M., Matthews, A., & Juneja, T. (2023) · Cureus · doi:10.7759/cureus.38498 · Cited by 35
Trends in Illicit Ketamine Seizures in the US From 2017 to 2022
Palamar, J. J., Wilkinson, S. T., Carr, T. H., Rutherford, C. G., & Cottler, L. B. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.1423 · Cited by 32
Saikosaponin d downregulates microRNA-155 and upregulates FGF2 to improve depression-like behaviors in rats induced by unpredictable chronic mild stress by negatively regulating NF-κB
Chao, B., Huang, S., Pan, J., Zhang, Y., & Wang, Y. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.01.008 · Cited by 32
Ketamine for depression clinical issues
Iqbal, S., & Mathew, S. J. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.02.005 · Cited by 33
Rapid acting antidepressants in the mTOR pathway: Current evidence
Athira, K. V., Mohan, A. S., & Chakravarty, S. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.07.022 · Cited by 34
Single, Fixed-Dose Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial
Domany, Y., & McCullumsmith, C. B. (2021) · Archives of Suicide Research · doi:10.1080/13811118.2021.1878078 · Cited by 33
Effect of Ketamine on Sleep in Treatment-Resistant Depression: A Systematic Review
Kwaśny, A., Włodarczyk, A., Ogonowski, D., & Cubała, W. J. (2023) · Pharmaceuticals · doi:10.3390/ph16040568 · Cited by 32
Metabolomics changes in brain-gut axis after unpredictable chronic mild stress
Xu, Q., Jiang, M. C., Gu, S., Zhang, X., Feng, G., Ma, X., Xu, S., Wu, E., Huang, J. H., & Wang, F. (2022) · Psychopharmacology · doi:10.1007/s00213-021-05958-w · Cited by 31
Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
Guo, H., Wang, B., Yuan, S., Wu, S., Liu, J., He, M., & Wang, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.849758 · Cited by 32
Saikosaponin D exerts antidepressant effect by regulating Homer1-mGluR5 and mTOR signaling in a rat model of chronic unpredictable mild stress
Liu, C., Chen, J., Liu, Y., Zhou, X., Zhang, M., Jiang, Y.-M., Ma, Q., Xue, Z., Zhao, Z., Li, X., et al. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00621-8 · Cited by 33
Targeting NMDA Receptors in Emotional Disorders: Their Role in Neuroprotection
Wang, S., Bian, L.-H., Yin, Y., & Guo, J. (2022) · Brain Sciences · doi:10.3390/brainsci12101329 · Cited by 33
The trouble with antidepressants: why the evidence overplays benefits and underplays risks - an essay by John B Warren
Warren, J. B. (2020) · BMJ · doi:10.1136/bmj.m3200 · Cited by 30
Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression
Jha, M. K., Wilkinson, S. T., Krishnan, K., Collins, K. A., Sanacora, G., Murrough, J. W., Goes, F. S., Altinay, M. I., Aloysi, A. S., Asghar‐Ali, A. A., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.17786 · Cited by 35
S100A10 and its binding partners in depression and antidepressant actions
Chen, M. X., Oh, Y., & Kim, Y. D. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.953066 · Cited by 32
Acupuncture may play a key role in anti-depression through various mechanisms in depression
Li, P., Zhao, J., Wei, X., Luo, L., Chu, Y., Zhang, T., Zhu, A., & Yan, J. (2024) · Chinese Medicine · doi:10.1186/s13020-024-00990-2 · Cited by 32
Influence of formulation and route of administration on ketamine’s safety and tolerability: systematic review
Glue, P., Russell, B., & Medlicott, N. J. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03047-z · Cited by 29
A key requirement for synaptic Reelin signaling in ketamine-mediated behavioral and synaptic action
Kim, J., Herz, J., Kavalali, E. T., & Monteggia, L. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103079118 · Cited by 29
Self-citation

Authors: Kim, J., Farchione, T., Potter, A., Chen, Q., & Temple, R.
Affiliations: United States Food and Drug Administration (US)
ORCID: Potter, Andrew
Chen, Qi
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2019-07-04
Volume: 381
Issue: 1
Pages: 1-4
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmp1903305
OpenAlex: W2946133992
Cited by: 333
References: 5
Citations by year: 2026: 26 · 2025: 47 · 2024: 56 · 2023: 37 · 2022: 55 · 2021: 51 · 2020: 48 · 2019: 13
FWCI: 25.88
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords: esketamine, treatment-resistant depression, FDA drug approval, NMDA receptor antagonists, antidepressants, abuse liability, risk evaluation and mitigation strategy
MeSH terms: Antidepressive Agents, Humans, Ketamine, United States, United States Food and Drug Administration, Drug Approval

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks